Literature DB >> 26373980

Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.

Quirino Lai1,2, Milton Inostroza3, Juan M Rico Juri4, Pierre Goffette5, Jan Lerut1.   

Abstract

OBJECTIVE: The aim of the present study was to investigate the role of different alpha-foetoprotein (AFP) determinations in order to propose a new model aimed at predicting intention-to-treat (ITT) death and post- liver transplantation (LT) recurrence in a cohort of patients with hepatocellular cancer (HCC) enlisted for LT.
BACKGROUND: Recent studies have increasingly focused on the role of AFP as a useful tool for patient selection in the setting of LT for HCC. However, no definitive AFP model has been definitively validated.
METHODS: A retrospective analysis was performed on 124 consecutive patients enlisted for LT in a UCL Brussels LT centre during the period January 2004 to March 2012. The median follow-up was 3.3 years (ranges: 1.7-6.3).
RESULTS: The area under the receiver-operating characteristic (AUROC) analysis showed the ability of the AFP delta-slope as a useful prognosticator of tumour-related drop-out and post-LT recurrence. In multivariate analyses, the delta-slope was an independent predictor of ITT death [hazard ratio (HR) = 1.014, P < 0.017] and post-LT tumour recurrence (HR = 1.020, P = 0.027). The 5-year ITT survival and disease-free survival rates were 66.0% versus 36.7% and 92.3% versus 53.8%, for patients meeting and exceeding the delta-slope cut-off value of 15 ng/ml/month, respectively.
CONCLUSIONS: Integration of the AFP delta-slope with conventional criteria may further improve patient selection and post-LT outcomes; prospective studies are needed to validate the present proposed model.
© 2015 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26373980      PMCID: PMC4644360          DOI: 10.1111/hpb.12486

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  25 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation.

Authors:  Neil Mehta; Francis Y Yao
Journal:  Liver Transpl       Date:  2013-10       Impact factor: 5.799

3.  Response to letter to the editors.

Authors:  Francis Y Yao; Bilal Hameed; Neil Mehta; John P Roberts
Journal:  Liver Transpl       Date:  2014-10       Impact factor: 5.799

4.  Liver transplantation for hepatocellular carcinoma in cirrhosis within the Eurotransplant area: an additional option with "livers that nobody wants".

Authors:  Georgios C Sotiropoulos; Andreas Paul; Ernesto Molmenti; Hauke Lang; Andrea Frilling; Bogdan P Napieralski; Silvio Nadalin; Jürgen Treckmann; Eirini I Brokalaki; Till Gerling; Christoph E Broelsch; Massimo Malagó
Journal:  Transplantation       Date:  2005-10-15       Impact factor: 4.939

Review 5.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

6.  Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study.

Authors:  Alessandro Cucchetti; Fabio Piscaglia; Antonia D'Errico Grigioni; Matteo Ravaioli; Matteo Cescon; Matteo Zanello; Gian Luca Grazi; Rita Golfieri; Walter Franco Grigioni; Antonio Daniele Pinna
Journal:  J Hepatol       Date:  2010-03-24       Impact factor: 25.083

7.  Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.

Authors:  Christophe Duvoux; Françoise Roudot-Thoraval; Thomas Decaens; Fabienne Pessione; Hanaa Badran; Tullio Piardi; Claire Francoz; Philippe Compagnon; Claire Vanlemmens; Jérome Dumortier; Sébastien Dharancy; Jean Gugenheim; Pierre-Henri Bernard; René Adam; Sylvie Radenne; Fabrice Muscari; Filomena Conti; Jean Hardwigsen; Georges-Philippe Pageaux; Olivier Chazouillères; Ephrem Salame; Marie-Noelle Hilleret; Pascal Lebray; Armand Abergel; Marilyne Debette-Gratien; Michael D Kluger; Ariane Mallat; Daniel Azoulay; Daniel Cherqui
Journal:  Gastroenterology       Date:  2012-06-29       Impact factor: 22.682

8.  Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.

Authors:  Neil Mehta; Jennifer L Dodge; Aparna Goel; John Paul Roberts; Ryutaro Hirose; Francis Y Yao
Journal:  Liver Transpl       Date:  2013-12       Impact factor: 5.799

Review 9.  Hepatocellular cancer: how to expand safely inclusion criteria for liver transplantation.

Authors:  Quirino Lai; Jan P Lerut
Journal:  Curr Opin Organ Transplant       Date:  2014-06       Impact factor: 2.640

10.  Liver transplantation for hepatocellular carcinoma: the Kyoto experience.

Authors:  Yasutsugu Takada; Shinji Uemoto
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-08-26       Impact factor: 7.027

View more
  3 in total

Review 1.  Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?

Authors:  Rafael S Pinheiro; Daniel R Waisberg; Lucas S Nacif; Vinicius Rocha-Santos; Rubens M Arantes; Liliana Ducatti; Rodrigo B Martino; Quirino Lai; Wellington Andraus; Luiz A C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2017-08-29

2.  Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.

Authors:  Arno Kornberg; Martina Schernhammer; Jennifer Kornberg; Helmut Friess; Katharina Thrum
Journal:  Dig Dis Sci       Date:  2018-09-27       Impact factor: 3.199

Review 3.  Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation.

Authors:  Marco Biolato; Tiziano Galasso; Giuseppe Marrone; Luca Miele; Antonio Grieco
Journal:  Cancers (Basel)       Date:  2021-12-17       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.